A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs

References

• Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. doi:10.1016/j.breast.2022.08.010
   PubMed Web of Science ®Google Scholar
• Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 1896;15:153. Internet[cited 2023 Apr 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518378/
   PubMedGoogle Scholar
• Yager JD, Davidson NE, Hopkins Bloomberg J. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;3543:270–282. Internet cited 2023 Apr 6. Available from: https://www.nejm.org/doi/10.1056/NEJMra050776
   PubMed Web of Science ®Google Scholar
• Trabert B, Sherman ME, Kannan N, et al. Progesterone and breast cancer. Endocr Rev. 2020;41(2):320–344. doi: 10.1210/endrev/bnz001
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Green MD, Hall RE, et al. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol. 1983;19(5):615–621. doi: 10.1016/0277-5379(83)90177-3
   PubMedGoogle Scholar
• Goldenberg GJ, Froese EK. Anatagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol. 1985;34(6):763–770. doi: 10.1016/0006-2952(85)90755-5
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Ravdin PM, et al. A randomized trial of adjuvant chemotherapy and tamoxifen timing in postmenopausal, endocrine-responsive, node-positive breast cancer. Lancet. 2009;374(9707):2055. Available from [cited 2023 Apr 17]. doi: 10.1016/S0140-6736(09)61523-3
   PubMed Web of Science ®Google Scholar
• Breast Cancer Trialists’ Collaborative Group (EBCTCG) E, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. doi: 10.1016/S0140-6736(11)60993-8
   PubMed Web of Science ®Google Scholar
• Breast Cancer - NCCN. Dec 24, 2022, Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast
   Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi: 10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Regan MM, Walley BA, Francis PA, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017;28(9):2225–2232. doi: 10.1093/annonc/mdx285
   PubMed Web of Science ®Google Scholar
• Li J, Ma Z, Jiang RW, et al. Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs. Expert Opin Drug Metab Toxicol. 2013;99:1085–1095. Internet cited 2023 Apr 5. Available from: https://www.tandfonline.com/doi/abs/10.1517/17425255.2013.802771
   PubMed Web of Science ®Google Scholar
• Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. JNCI. 1995;87(10):746–750. doi: 10.1093/jnci/87.10.746
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380(13):1226–1234. doi: 10.1056/NEJMoa1811714
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227(2):115–124. doi: 10.1016/j.canlet.2004.10.007
   PubMed Web of Science ®Google Scholar
• Bewick PM. Medicinal natural products: a biosynthetic approach. (NY): Wiley; 2002. doi: 10.1002/0470846275
   Google Scholar
• Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand. 2015;94Suppl 161:8–16. Internet [cited 2023 Apr 19] Available from: https://pubmed.ncbi.nlm.nih.gov/26358238/
   PubMedGoogle Scholar
• Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988;33(5):500–508.
   PubMed Web of Science ®Google Scholar
• Frasor J, Stossi F, Danes JM, et al. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004;64(4):1522–1533. doi: 10.1158/0008-5472.CAN-03-3326
   PubMed Web of Science ®Google Scholar
• Hudson CE, Schulte BA, Sutter TR, et al. Steroid hormones modulate expression of cytochrome P450 enzymes in male hamster reproductive tract and leiomyosarcomas. Carcinogenesis. 2001;22(5):763–770. doi: 10.1093/carcin/22.5.763
   PubMed Web of Science ®Google Scholar
• Williams ET, Leyk M, Wrighton SA, et al. Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004;311(2):728–735. Internet. [cited 2023 Apr 19]. 10.1124/jpet.104.068908
   PubMed Web of Science ®Google Scholar
• Riordan JR, Deuchars K, Kartner N, et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 1985;316(6031):817–819. doi: 10.1038/316817a0
   PubMed Web of Science ®Google Scholar
• Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47(3):381–389. doi: 10.1016/0092-8674(86)90595-7
   PubMed Web of Science ®Google Scholar
• Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Sci (1979). 1986;232(4750):643–645. doi: 10.1126/science.3457471
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Hrycyna CA, Schoenlein PV, et al. Genetic analysis of the multidrug transporter. Ann Rev Genet. 1995;29(1):607–649. doi: 10.1146/annurev.ge.29.120195.003135
   PubMedGoogle Scholar
• Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987;84(9):3004–3008. doi: 10.1073/pnas.84.9.3004
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers. JNCI. 1989;81(2):116–124. doi: 10.1093/jnci/81.2.116
   PubMedGoogle Scholar
• Mutoh K, Tsukahara S, Mitsuhashi J, et al. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci. 2006;9711:1198–1204. Internet [cited 2023 Apr 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/16925584/
   PubMed Web of Science ®Google Scholar
• Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun. 2001;280(5):1216–1223. Internet [cited 2023 Apr 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/11162657/
   PubMed Web of Science ®Google Scholar
• Yang CH, Schneider E, Kuo ML, et al. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol. 2000;60(6):831–837. doi: 10.1016/S0006-2952(00)00396-8
   PubMed Web of Science ®Google Scholar
• Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000;113(11):2011–2021. doi: 10.1242/jcs.113.11.2011
   PubMed Web of Science ®Google Scholar
• Austin Doyle L, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;9526:15665–15670. Internet [cited 2023 Apr 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/9861027/
   PubMed Web of Science ®Google Scholar
• Annilo T, Tammur J, Hutchinson A, et al. Human and mouse orthologs of a new ATP-binding cassette gene, ABCG4. Cytogenet Cell Genet. 2001;94(3–4):196–201. doi: 10.1159/000048816
   PubMedGoogle Scholar
• Imai Y, Ishikawa E, Asada S, et al. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res. 2005;65(2):596–604. Internet [cited 2023 Apr 20]. Available from: https://aacrjournals.org/cancerres/article/65/2/596/518300/Estrogen-Mediated-Post-transcriptional-Down
   PubMed Web of Science ®Google Scholar
• Chen C, Staudinger JL, Klaassen CD. NUCLEAR RECEPTOR, PREGNANE X RECEPTOR, is REQUIRED for INDUCTION of UDP-GLUCURONOSYLTRANSFERASES in MOUSE LIVER by PREGNENOLONE-16α-CARBONITRILE. Drug Metab Dispos. 2003;317:908–915. Internet [cited 2023 Apr 19] Available from: https://www.researchgate.net/publication/10700993_Nuclear_receptor_pregnane_X_receptor_is_required_for_induction_of_UDP-glucuronosyltransferases_in_mouse_liver_by_16aa-carbonitrile
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA. 2001;98(6):3369. InternetAvailable from /pmc/articles/PMC30660/. [cited 2023 Apr 19]. 10.1073/pnas.051551698
   PubMed Web of Science ®Google Scholar
• Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002;277(4):2908–2915. Internet [cited 2023 Apr 19]. Available from: https://pubmed.ncbi.nlm.nih.gov/11706036/
   PubMed Web of Science ®Google Scholar
• Xie W, Yeuh MF, Radominska-Pandya A, et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci U S A. 2003;100(7):4150–4155. Internet [cited 2023 Apr 19]. Available from: https://pubmed.ncbi.nlm.nih.gov/12644700/
   PubMed Web of Science ®Google Scholar
• Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 2001;755:584–590. Internet [cited 2023 Apr 19]. Available from: https://www.nature.com/articles/nm0501_584
   PubMed Web of Science ®Google Scholar
• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by Rifampin. J Biol Chem. 2001;276(18):14581–14587. Internet [cited 2023 Apr 19]. Available from: http://www.jbc.org/article/S0021925819567357/fulltext
   PubMed Web of Science ®Google Scholar
• Li J, Ma Z, Jiang R, et al. Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs. Expert Opin Drug Metab Toxicol. 2013;9(9):1085–1095. doi: 10.1517/17425255.2013.802771
   PubMed Web of Science ®Google Scholar
• Ding L, Cao J, Lin W, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 2020;21(6):1960. doi: 10.3390/ijms21061960
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi: 10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi: 10.1056/NEJMoa1810527
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–950. doi: 10.1056/NEJMoa2114663
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–524. doi: 10.1056/NEJMoa1911149
   PubMed Web of Science ®Google Scholar
• Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316. doi: 10.1056/NEJMoa1903765
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2. JAMA Oncol. 2020;6(1):116. doi: 10.1001/jamaoncol.2019.4782
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5(1):5. doi: 10.1038/s41523-018-0097-z
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77–90. doi: 10.1016/S1470-2045(22)00694-5
   PubMed Web of Science ®Google Scholar
• Bidard F-C, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. JCO. 2022;40(28):3246–3256. doi: 10.1200/JCO.22.00338
   PubMed Web of Science ®Google Scholar
• Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345–357. doi: 10.1016/S1470-2045(19)30817-4
   PubMed Web of Science ®Google Scholar
• Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol. 2022;40(17_suppl):LBA1001–LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001
   Web of Science ®Google Scholar
• Rugo HS, Im S-A, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated erbb2-positive advanced breast cancer. JAMA Oncol. 2021;7(4):573. doi: 10.1001/jamaoncol.2020.7932
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–117. doi: 10.1016/S0140-6736(22)02420-5
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, Feng Y-H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. JCO. 2020;38(27):3138–3149. doi: 10.1200/JCO.20.00147
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377. doi: 10.1016/S1470-2045(15)00551-3
   PubMed Web of Science ®Google Scholar
• Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321–329. doi: 10.1016/j.annonc.2021.12.005
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi: 10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–226. doi: 10.1056/NEJMoa2202809
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi: 10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. doi: 10.1056/NEJMoa2028485
   PubMed Web of Science ®Google Scholar
• Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–1268. doi: 10.1016/j.annonc.2022.09.159
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi: 10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526–1535. doi: 10.1016/j.annonc.2020.08.2098
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: IBRANCE. Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf
   Google Scholar
• Highlights of prescribing information: KISQALI. (n.d.). Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209092s003lbl.pdf
   Google Scholar
• Samant TS, Huth F, Umehara K, et al. Ribociclib drug‐drug interactions: clinical evaluations and physiologically‐based pharmacokinetic modeling to guide drug labeling. Clin Pharmacol Ther. 2020;108(3):575–585. doi: 10.1002/cpt.1950
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. VERZENIO. (n.d.). Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf
   Google Scholar
• Choi S-Y, Koh KH, Jeong H. Isoform-specific regulation of cytochromes p450 expression by estradiol and progesterone. Drug Metab Dispos. 2013;41(2):263–269. doi: 10.1124/dmd.112.046276
   PubMed Web of Science ®Google Scholar
• Ferraro E, Walsh EM, Tao JJ, et al. Accelerating drug development in breast cancer: new frontiers for ER inhibition. Cancer Treat Rev. 2022;109:102432. doi:10.1016/j.ctrv.2022.102432
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information for orserdu. Apr 17, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf
   Google Scholar
• Conlan MG, de Vries EFJ, Glaudemans A, et al. Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women. Eur J Drug Metab Pharmacokinet. 2020;45(5):675–689. doi: 10.1007/s13318-020-00635-3
   PubMed Web of Science ®Google Scholar
• Koenen A, Köck K, Keiser M, et al. Steroid hormones specifically modify the activity of organic anion transporting polypeptides. Eur J Pharmaceut Sci. 2012;47(4):774–780. doi: 10.1016/j.ejps.2012.08.017
   PubMed Web of Science ®Google Scholar
• André F, Hee Park Y, Kim S-B, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773–1785. doi: 10.1016/S0140-6736(23)00725-0
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi: 10.1056/NEJMoa1914510
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information the recommended dosage of ENHERTU. Apr 17, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf
   Google Scholar
• Trastuzumab deruxtecan. Uses, interactions, mechanism of action | DrugBank online. (n.d.). Apr 17, 2023, Available from: https://go.drugbank.com/drugs/DB14962
   Google Scholar
• Annals of Oncology . 2019;30suppl_5:v104–v142.10.1093/annonc/mdz242
   Google Scholar
• Takahashi S, Karayama M, Takahashi M, et al. Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors. Clin Cancer Res. 2021;27(21):5771–5780. doi: 10.1158/1078-0432.CCR-21-1560
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information see full prescribing information. TRODELVY. Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761115s023lbl.pdf
   Google Scholar
• Jandu H, Aluzaite K, Fogh L, et al. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer. 2016;16(1):34. doi: 10.1186/s12885-016-2071-1
   PubMedGoogle Scholar
• Seelig A. P-Glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers. Front Oncol. 2020;10:10. doi: 10.3389/fonc.2020.576559
   PubMed Web of Science ®Google Scholar
• Jeong H, Choi S, Song JW, et al. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008;38(1):62–75. doi: 10.1080/00498250701744633
   PubMed Web of Science ®Google Scholar
• Vore M, Leggas M. Progesterone acts via progesterone receptors a and B to regulate breast cancer resistance protein expression: Fig. 1. Mol Pharmacol. 2008;73(3):613–615. doi: 10.1124/mol.107.044289
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: Tukysa. Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf
   Google Scholar
• Food and Drug Administration. MARGENZA. (n.d.). Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf
   Google Scholar
• Food and Drug Administration. KEYTRUDA. Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s096lbl.pdf
   Google Scholar
• Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12(10):1247–1253. doi: 10.1080/17425255.2016.1216976
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: impassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–993. doi: 10.1016/j.annonc.2021.05.355
   PubMed Web of Science ®Google Scholar
• Friedman D, Netti F, Schreiber AD. Effect of estradiol and steroid analogues on the clearance of immunoglobulin G-coated erythrocytes. J Clin Investig. 1985;75(1):162–167. doi: 10.1172/JCI111669
   PubMed Web of Science ®Google Scholar
• Shu-Kuang H, Mitcho YL, Rath NC. Effect of estradiol on interleukin 1 synthesis by macrophages. Int J Immunopharmacol. 1988;10(3):247–252. doi: 10.1016/0192-0561(88)90055-0
   PubMed Web of Science ®Google Scholar
• Unger JM, Vaidya R, Albain KS, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474–1486. doi: 10.1200/JCO.21.02377
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737–746. doi: 10.1016/S1470-2045(18)30261-4
   PubMed Web of Science ®Google Scholar
• Nicolini A, Ferrari P, Carpi A. Immune checkpoint inhibitors and other immune therapies in breast cancer: a new paradigm for prolonged adjuvant immunotherapy. Biomedicines. 2022;10(10):2511. doi: 10.3390/biomedicines10102511
   PubMed Web of Science ®Google Scholar
• Food and drug administration. LYNPARZA. Apr 18, 2023, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf
   Google Scholar
• Dias MP, Moser SC, Ganesan S, et al. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773–791. doi: 10.1038/s41571-021-00532-x
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information. TALZENNA. Apr 18, 2023, Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf
   Google Scholar
• Zhou S, Liu Y, Jin L, et al. Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production. J Steroid Biochem Mol Biol. 2021;209:105853. doi:10.1016/j.jsbmb.2021.105853
   PubMed Web of Science ®Google Scholar